Latest news about Jenburkt Pharmaceuticals
Jenburkt Pharmaceuticals
1,126.00
-2.10(-0.19%)
Company Performance:
View Company Insights1D-0.19%
1M-2.49%
6M+3.40%
1Y-13.32%
5Y+132.31%
More news about Jenburkt Pharmaceuticals
28Oct 25
Jenburkt Pharmaceuticals Reports 10.5% Revenue Growth in Q2 FY2026
Jenburkt Pharmaceuticals Limited announced strong Q2 FY2026 results. Revenue from operations increased by 10.5% to Rs 4,555.70 lacs, while profit after tax grew by 11.3% to Rs 1,133.20 lacs compared to Q2 FY2025. Total income rose by 10.6% to Rs 4,763.66 lacs. For the half-year ended September 30, 2025, total revenue reached Rs 8,108.40 lacs, a 10% increase from the previous year. The company continues to focus exclusively on the pharmaceuticals segment. The Board of Directors approved these unaudited financial results on October 28, 2025, following a limited audit review by D.R. Mehta & Associates.
20May 25
Jenburkt Pharmaceuticals Reports Strong Q4 Results, Announces Dividend
Jenburkt Pharmaceuticals released its Q4 financial results, showing significant growth. Revenue increased by 5.80% to ₹410.50 crore. EBITDA rose by 10.25% to ₹108.60 crore, with the EBITDA margin expanding to 26.45%. Net profit grew by 8.10% to ₹85.40 crore. The company also announced a dividend of ₹18.00 per equity share.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Cipla
Dr Reddys Laboratories
Zydus Life Science
Lupin
Mankind Pharma
Aurobindo Pharma
Laurus Labs
1,863.30
(-0.59%)
6,718.00
(-0.53%)
4,519.90
(+0.34%)
1,440.20
(+0.16%)
1,353.60
(+1.90%)
1,101.90
(+0.24%)
2,344.40
(-0.98%)
2,462.10
(-0.84%)
1,555.60
(+1.63%)
1,450.20
(-0.28%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
